Large B-Cell Lymphoma After CD19 CAR-T Failure: Updated Real-World Outcomes, Prognostic Factors, and Prediction Models.
Real-world data clarifies which lymphoma patients survive after CAR-T failure and what factors drive their outcomes.
Updated multicenter real-world data characterize outcomes and identify prognostic factors for large B-cell lymphoma patients who progress after CD19 CAR-T cell therapy. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- cohort_study
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Transplant Cell Ther
Why it surfaced
Post-CD19 CAR-T failure represents the highest unmet need in aggressive lymphoma; multicenter real-world design with prediction models provides immediately actionable clinical data for a setting lacking randomized trial evidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.